Characteristics | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
HR (95%CI) | P valuea | HR (95%CI) | P valuea | |
Sex | ||||
 Female | 1 | (Reference) |  |  |
 Male | 1.30 (0.79–2.12) | 0.305 |  |  |
EOCRC or LOCRC | ||||
 LOCRC | 1 | (Reference) | 1 | (Reference) |
 EOCRC | 0.55 (0.28–1.11) | 0.096 | 0.28 (0.13–0.62) | 0.002 |
Family history of tumours | ||||
 No | 1 | (Reference) | 1 | (Reference) |
 Yes | 0.37 (0.09–1.49) | 0.160 | 0.57 (0.12–2.80) | 0.488 |
BMI (kg/m2) | ||||
 18.5 to 24 | 1 | (Reference) |  |  |
 < 18.5 | 0.97 (0.52–1.83) | 0.927 |  |  |
 ≥ 24 | 0.78 (0.47–1.28) | 0.320 |  |  |
Haemoglobin (g/L) | ||||
 > 110 | 1 | (Reference) | 1 | (Reference) |
 ≤ 100 | 1.80 (1.17–2.77) | 0.007 | 1.75 (1.07–2.84) | 0.025 |
Platelet counts (109/L) | ||||
 ≤ 300 | 1 | (Reference) |  |  |
 > 300 | 1.20 (0.76–1.89) | 0.431 |  |  |
WBC (109/L) | ||||
 ≤ 10 | 1 | (Reference) |  |  |
 > 10 | 1.19 (0.60–2.38) | 0.622 |  |  |
CEA (ng/mL) | ||||
 ≤ 10 | 1 | (Reference) | 1 | (Reference) |
 > 10 | 2.65 (1.72–4.09) | < 0.001 | 1.38 (0.82–2.31) | 0.220 |
CA199 (kU/L) | ||||
 ≤ 27 | 1 | (Reference) | 1 | (Reference) |
 > 27 | 2.24 (1.44–3.47) | < 0.001 | 1.04 (0.61–1.78) | 0.884 |
CA125 (kU/L) | ||||
 ≤ 35 | 1 | (Reference) | 1 | (Reference) |
 > 35 | 5.88 (3.49–9.91) | < 0.001 | 4.19 (2.23–7.85) | < 0.001 |
CA153 (kU/L) | ||||
 ≤ 25 | 1 | (Reference) | 1 | (Reference) |
 > 25 | 5.78 (1.79–18.69) | 0.003 | 3.65 (0.98–13.57) | 0.054 |
AFP (ng/mL) | ||||
 ≤ 7 | 1 | (Reference) |  |  |
 > 7 | 0.68 (0.22–2.16) | 0.516 |  |  |
Type of ascites | ||||
 No | 1 | (Reference) | 1 | (Reference) |
 Serous | 1.28 (0.62–2.66) | 0.505 | 0.55 (0.24–1.24) | 0.150 |
 Bloody | 6.78 (2.12–21.74) | 0.001 | 3.53 (0.87–14.27) | 0.077 |
Tumor location | ||||
 Right colon | 1 | (Reference) |  |  |
 Left colon | 0.68 (0.35–1.32) | 0.257 |  |  |
 Rectum | 0.77 (0.42–1.41) | 0.398 |  |  |
 Multiple segment | 0.68 (0.38–1.23) | 0.200 |  |  |
Radical or palliative surgery | ||||
 Radical | 1 | (Reference) | 1 | (Reference) |
 Palliative | 6.45 (4.17–9.96) | < 0.001 | 2.87 (1.17–7.02) | 0.021 |
 (y)pTNM staging | ||||
 0–I | 1 | (Reference) | 1 | (Reference) |
 II | 3.13 (0.72–13.6) | 0.129 | 2.77 (0.63–12.22) | 0.178 |
 III | 5.32 (1.26–22.53) | 0.023 | 5.34 (1.24–22.98) | 0.025 |
 IV | 17.27 (4.18–71.47) | < 0.001 | 5.89 (1.16–29.77) | 0.032 |
Number of retrieved lymph nodes | ||||
 < 12 | 1 | (Reference) | 1 | (Reference) |
 ≥ 12 | 1.82 (0.94–3.53) | 0.075 | 1.55 (0.75–3.22) | 0.240 |
Gross classification | ||||
 Mass type | 1 | (Reference) |  |  |
 Infiltration type | 1.75 (0.53–5.71) | 0.355 |  |  |
 Ulceration type | 0.86 (0.55–1.34) | 0.499 |  |  |
Histological type | ||||
 Classical adenocarcinoma | 1 | (Reference) |  |  |
 Mucinous adenocarcinoma | 0.64 (0.26–1.57) | 0.328 |  |  |
 Signet ring cell carcinoma | 0 (0-Inf) | 0.994 |  |  |
Differentiation grade | ||||
 Well differentiated | 1 | (Reference) |  |  |
 Moderately differentiated | 1.15 (0.65–2.02) | 0.634 |  |  |
 Poorly differentiated | 1.09 (0.53–2.23) | 0.824 |  |  |
Vessel invasion | ||||
 Negative | 1 | (Reference) | 1 | (Reference) |
 Positive | 1.82 (1.11–2.99) | 0.018 | 1.09 (0.60–1.98) | 0.780 |
Neural invasion | ||||
 Negative | 1 | (Reference) | 1 | (Reference) |
 Positive | 2.37 (1.45–3.87) | 0.001 | 1.32 (0.71–2.44) | 0.378 |
Ki67 expression | ||||
 Low | 1 | (Reference) | 1 | (Reference) |
 Moderate | 0.64 (0.28–1.43) | 0.275 | 1.10 (0.45–2.66) | 0.833 |
 High | 0.58 (0.30–1.13) | 0.111 | 1.00 (0.47–2.13) | 0.999 |
MMR status | ||||
 pMMR | 1 | (Reference) | 1 | (Reference) |
 dMMR | 0.48 (0.22–1.04) | 0.063 | 0.77 (0.32–1.83) | 0.551 |